Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 17/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 3/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 3/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 0.83 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.66 |
| ▸ | WEE1 | P30291 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762258 | 0.91 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL5764642 | 0.88 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL5763017 | 0.88 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL5763919 | 0.85 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL6641430 | 0.84 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL5763198 | 0.83 | FGFR1 (0.75) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL5762061 | 0.82 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL6641500 | 0.81 | FGFR1 (1.00) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL5764398 | 0.81 | FGFR1 (0.82) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL25399236 | 0.81 | FGFR1 (0.71) | FGFR1SRCFGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | claimed |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | claimed |
| EP-1201765-A2 | Cellular kinases involved in cytomegalovirus infection and their inhibition | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-05-02 | — | — | EP | claimed |
| US-5733914-A | Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | claimed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | claimed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | claimed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | disclosed |
| US-6849409-B2 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-1201765-A2 | Cellular kinases involved in cytomegalovirus infection and their inhibition | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | CDC42BPG, CDC42BPB, CDC7 | FGFR1 2823/4885SRC 431/4885FGFR2 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.